Arkolith/Insider Trading/NXEN/Form 4

Wasoff Evan L

Chief Financial OfficerNEXIEN BIOPHARMA, INC. (NXEN) · full profile →Form 4 · filed Oct 18, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 17, 2022Grant(A)250K——3.5M

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001214659-22-012390) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML